Docta Complutense
Publication
Artículo científico (JournalArticle)
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR
Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been hampered by dose-limiting liver toxicity. We have previously developed an EGFR-targeted 4-1BBagonistic trimerbody (1D8N/CEGa1) that induces potent anti-tumor immunity without systemic toxicity, in immunocompetent mice bearing murine colorectal carcinoma cells expressing human EGFR. Here, we study the impact of human EGFR expression on mouse liver in the toxicity profile of 1D8N/CEGa1. Systemic administration of IgG-based anti-4-1BB agonist resulted in nonspecific immune stimulation and hepatotoxicity in a liver-specific human EGFR-transgenic immunocompetent mouse, whereas in 1D8N/CEGa1-treated mice no such immune-related adverse effects were observed. Collectively, these data support the role of FcgR interactions in the major offtumor toxicities associated with IgG-based 4-1BB agonists and further validate the safety profile of EGFR-targeted Fc-less 4-1BB-agonistic trimerbodies in systemic
cancer immunotherapy protocols.
Project:
European Commission / Seventh Framework Programme 602262
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2017-89437-P
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-110405RB-I00
,
Ministerio de Economía y Competitividad / Not available PI16/00357